In the early stages of tumor progression, the presence of cDC1s in the TME is limited due to the preferential recruitment of tumor‐promoting immune cells by chemokines such as C‐X‐C motif chemokine ligand 1 (CXCL1), C‐C motif chemokine ligand 2 (CCL2), and CCL20, which are secreted by tumor cells [68]. The gene discussed is CCL20; the disease is neoplasm.